The sphenopalatine ganglion (SPG) plays a pivotal role in cluster headache (CH) pathophysiology as the major efferent parasympathetic relay. We evaluated the long-term effectiveness of SPG stimulation in medically refractory, chronic CH patients.
Chronic cluster headache (CCH) is a debilitating disorder with a significant impairment for the patient leading to low quality of life. The sphenopalatine ganglion (SPG) proved to play an important role in CCH pathophysiology.
Cluster headache is a rare form of primary headache characterised by intense unilateral pain and autonomous nerve symptoms. Pharmacological treatments are sometimes insufficient, which calls for surgical alternatives in treatment refractory cases. Stimulation of the sphenopalatine ganglion (SPG) is a new method shown to be effective for preventing and treating attacks.
The ATI SPG microstimulator is designed to be fixed on the posterior maxilla, with the integrated lead extending into the pterygopalatine fossa to electrically stimulate the sphenopalatine ganglion (SPG) as a treatment for cluster headache. Preoperative surgical planning to ensure the placement of the microstimulator in close proximity (within 5 mm) to the SPG is critical for treatment efficacy. The aim of this study was to improve the surgical procedure by navigating the initial dissection prior to implantation using a passive optical navigation system and to match the post-operative CBCT images with the preoperative treatment plan to verify the accuracy of the intraoperative placement of the microstimulator.
The pain and autonomic symptoms of cluster headache result from activation of the trigeminal parasympathetic reflex, mediated through the SPG [1,2]. We aimed to investigate the safety and efficacy of SPG stimulation for the acute treatment of CCH.
The pain and autonomic symptoms of cluster headache (CH) result from activation of the trigeminal parasympathetic reflex, mediated through the sphenopalatine ganglion (SPG). We investigated the safety and efficacy of on-demand SPG stimulation for chronic CH (CCH).
Condition: Cluster HeadacheIntervention: Sponsor: Autonomic Technologies, Inc.Active, not recruiting – verified May 2017 Source: Cluster Headache Clinical Trials